33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparison of TAS0953/HM06 and selpercatinib in RET fusion-driven preclinical disease models of intracranial metastases
    Meeting Abstract

    Odintsov, I.; Lui, A. J. W.; Ishizawa, K.; Miyazaki, I.; Khodos, I.; Wakayama, K.; Vojnic, M.; Hagen, C. J.; Chang, Q.; Bonifacio, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Building a model to predict the risk of multiple severe neurotoxicities in cancer survivors after cisplatin treatment
    Meeting Abstract

    Nakshatri, S.; Shuey, M.; Shahbazi, M.; Trendowski, M.; Dinh, P. C.; Feldman, D. R.; Hamilton, R. J.; Vaughn, D. J.; Fung, C.; Kollmannsberger, C. K.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)-A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation
    Meeting Abstract

    Niazi, T.; McBride, S. M.; Williams, S.; Davis, I. D.; Stockler, M. R.; Martin, A. J.; Bracken, K.; Roncolato, F.; Horvath, L.; Sengupta, S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
    Meeting Abstract

    Nowakowski, G. S.; Yoon, D. H.; Joffe, E.; Zinzani, P. L.; Sabatelli, L.; Waltl, E. E.; Alvero, C. G.; Hess, G.; Riedell, P. A.; Kim, K.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase III study (daNIS-2) of the anti-TGF-β monoclonal antibody (mAb) NIS793 with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)
    Meeting Abstract

    O'Reilly, E. M.; Golan, T.; Ikeda, M.; Milella, M.; Taieb, J.; Wainberg, Z. A.; Wang, L. W.; Gyambibi, N.; Lopez-Martin, E. M.; Xu, K.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Long-term outcomes of adrenal insufficiency (AI) due to anti-PD(L)-1 immune checkpoint inhibitors (ICI) among patients with cancer
    Meeting Abstract

    Nguyen, B.; Shah, N. J.; Knezevic, A.; Newman, S.; Fitzgerald, K. N.; Kotecha, R.; Lee, C. H.; Carlo, M. I.; Aggen, D. H.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A single-arm feasibility trial of memantine to prevent chemotherapy-related cognitive decline in patients with early breast cancer
    Meeting Abstract

    Nakamura, Z.; Deal, A. M.; Park, E. M.; Stanton, K.; Lopez, Y.; Quillen, L. J.; Kelly, E. O.; Heiling, H. M.; Nyrop, K. A.; Ray, E. M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Central nervous system (CNS) outcomes and progression patterns in patients with RET fusion-positive lung cancers treated with selpercatinib
    Meeting Abstract

    Murciano-Goroff, Y. R.; Falcon, C. J.; Lin, S. T.; Dhawan, A.; Grimaldi, G.; Liu, D.; Wilhelm, C.; Thomas, R.; Iasonos, A.; Drilon, A. E.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma
    Meeting Abstract

    Movva, S.; Avutu, V.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; Nacev, B. A.; Rosenbaum, E.; Thornton, K. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Presence of immune infiltrates, increased expression of transposable elements, and viral response pathways in sarcoma associate with response to checkpoint inhibition
    Meeting Abstract

    Nacev, B. A.; Bradic, M.; Richards, A. L.; Kelly, C. M.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Chi, P.; Movva, S.; Thornton, K. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save